MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
June 10, 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the positive...
Santhera gibt den Beginn eines Early-Access-Programms für AGAMREE® in China durch seinen Partner Sperogenix bekannt
June 10, 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Schweiz, 10. Juni 2024 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Partnerunternehmen Sperogenix Therapeutics in China ein Frühzugangsprogramm (Early Access Program, EAP)...
Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix
June 10, 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Switzerland, June 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for AGAMREE®...
BioSenic publie ses résultats annuels 2023
June 06, 2024 15:05 ET
|
BioSenic
COMMUNIQUÉ DE PRESSE – INFORMATION REGLEMENTEE BioSenic a arrêté le recrutement des patients pour son essai de phase 2b ALLOB à la mi-2023. BioSenic a préparé un plan de restructuration global...
BioSenic announces 2023 full year results
June 06, 2024 15:05 ET
|
BioSenic
PRESS RELEASE - REGULATED INFIRMATION BioSenic stopped the patient recruitment for its Phase 2b ALLOB trial in mid-2023. BioSenic has prepared a global restructuring plan covering the years...
Global Maritime Safety System Market Forecast Report 2024-2029: Port & Critical Infrastructure and Loss & Prevention Detection to Account for Largest Shares of North American Market in 2024
June 06, 2024 08:15 ET
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Global Maritime Safety System Market by Offering (Solutions, Services), Security Type (Coastal Security, Crew Security), System (AIS, GMDSS, LRIT),...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
May 25, 2024 06:15 ET
|
Novartis Pharma AG
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction...
BioSenic fait le point sur ses activités du premier trimestre 2024
May 24, 2024 11:00 ET
|
BioSenic
COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Mont-Saint-Guibert, Belgique, le 24 mai 2024 à 17h00 CEST – BIOSENIC (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée...
BioSenic provides First Quarter 2024 Business Update
May 24, 2024 11:00 ET
|
BioSenic
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, May 24, 2024, 17.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious...
Acceleware Ltd. Reports First Quarter 2024 Financial and Operating Results
May 23, 2024 17:52 ET
|
Acceleware Limited
CALGARY, Alberta, May 23, 2024 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of transformative technologies targeting the decarbonization of...